INT232387

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.32
Pain Relevance 0.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (CD22) plasma membrane (CD22)
Anatomy Link Frequency
B-cell 3
CD22 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 116 100.00 Very High Very High Very High
Osteoarthritis 48 98.80 Very High Very High Very High
Antihistamine 6 96.80 Very High Very High Very High
Paracetamol 4 96.08 Very High Very High Very High
cytokine 18 7.88 Low Low
Inflammation 24 5.00 Very Low Very Low Very Low
corticosteroid 14 5.00 Very Low Very Low Very Low
tolerance 6 5.00 Very Low Very Low Very Low
methotrexate 5 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 116 100.00 Very High Very High Very High
Lymphatic System Cancer 32 99.76 Very High Very High Very High
Frailty 49 98.80 Very High Very High Very High
Hypersensitivity 6 94.20 High High
Disease 36 87.96 High High
Apoptosis 18 87.36 High High
Systemic Lupus Erythematosus 46 81.48 Quite High
Adhesions 4 79.08 Quite High
Autoimmune Disease 44 67.20 Quite High
Death 2 46.12 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
class, which specifically binds to the CD22 antigen in B-cells.
CD22 Binding (binds) of in B-cells
1) Confidence 0.32 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.47 Pain Relevance 0.14
In the situation of B-cell lymphomas expressing CD22, epratuzumab, when immobilized, inhibited cell proliferation, but did not do so when not immobilized, even when crosslinked (Carnahan et al 2003, 2007).
CD22 Binding (crosslinked) of in B-cell associated with lymphatic system cancer
2) Confidence 0.28 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.61 Pain Relevance 0
All pathways/complexes were specific for RA, including the vascular endothelial growth factor (VEGF) and the B-cell receptor signaling pathways.
B-cell receptor Binding (specific) of in B-cell associated with rheumatoid arthritis
3) Confidence 0.03 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575612 Disease Relevance 1.25 Pain Relevance 0.59

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox